Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), the holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci133 injection was accepted. This drug is a PTH polypeptide and anti-RANKL antibody fusion protein independently developed by Jinsai Pharmaceutical. It belongs to class 1 of therapeutic biological products and is intended to treat osteoporosis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.